Data protection and cyber matters, financing for acquisitions and high-profile appeals of decisions made by the Competition and Markets Authority stand out as areas of activity for the team at Clifford Chance LLP. Stephen Reese and Gareth Camp jointly oversee the practice. Reese is equipped to advise clients on the UK and EU regulatory aspects of pharmaceuticals biologics and medical devices and their interplay with IP strategy, while Camp is frequently tasked with leading life sciences and healthcare transactions. Corporate compliance and investigations partner Luke Tolaini‘s practice extends to crisis management and ethical and compliance failings. Alex Walker focuses his practice on advising clients on the protection, exploitation, use and enforcement of their IP rights.
Legal 500 redaktioneller Kommentar
- Profil
Kernmandanten
- Pfizer
- Cinven
- EQT Infrastructure
- GE HealthCare
- Xellia Pharmaceuticals ApS and
- Alpharma LLC ("Alpharma")
- Gilead Sciences
- Her Majesty's Government (HMG), Department for Business, Energy and Industrial Strategy (BEIS)
Highlight-Mandate
- Acting for Cinven in relation to a high-profile appeal before the Competition Appeal Tribunal ("CAT") against CMA Decisions for the alleged antitrust infringements of a former portfolio company active in generic pharmaceuticals, now named Advanz.
- Advised a Medicinal Cannabis developer and manufacturer in connection with an IP licensing contractual dispute concerning their global development and commercialisation of Cannabis medicinal products.
- Assisting a global pharmaceutical and healthcare corporation with various data protection and cyber matters.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Stephen Reese; Gareth Camp
Weitere Kernanwält*innen
Luke Tolaini; Alex Walker